Role Reversal: Big Pharma Provides Rich Pickings for Biotech
Executive Summary
Big Pharma is looking for innovative ways to realize value from non-core assets--including discovery technologies. The U.K.'s Proteome Sciences is the latest European biotech to benefit, as Aventis clears out its house.